The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials

Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibitors. Ramucirumab, an anti-VEGFR2 antibody, has shown efficacy in GC, but the benefits are li...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeed, Anwaar, Park, Robin, Sun, Weijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802258/
https://www.ncbi.nlm.nih.gov/pubmed/33436042
http://dx.doi.org/10.1186/s13045-021-01034-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802258/
https://www.ncbi.nlm.nih.gov/pubmed/33436042
http://dx.doi.org/10.1186/s13045-021-01034-0

Ejemplares similares